Statistics from Altmetric.com
An association between periodontitis and rheumatoid arthritis (RA) has been proposed based on observations of increased risk of periodontitis in patients with RA as well as the presence of antibodies to citrullinated protein antigens (ACPAs) and rheumatoid factor (RF) in serum and gingiva of patients with periodontitis.1–3 Additionally, smoking is one of the most important risk factors for both periodontitis and RA, and predispose for the development of seropositive RA.4–6 We have previously reported that smokers with RA have increased prevalence of periodontitis as compared with never smokers in the Swedish population-based case–control study EIRA (Epidemiological Investigation of Rheumatoid Arthritis).7 The objective of the current study was to further investigate the effects of smoking on the risk of periodontitis in seropositive and seronegative (ACPA/RF) subsets of RA.
Data on periodontal status (years 2008–2012) were retrieved from the Swedish Dental Health Registry (DHR) for 2327 patients with established RA (1469/852 ACPA-positive/ACPA-negative and 1505/822 RF-positive/RF-negative, respectively) included in the EIRA study (years 1996–2009) as previously described.7 Periodontal diagnosis was based on diagnostic codes for periodontitis, peri-implantitis and increased risk of periodontitis/peri-implantitis, registered by the patients’ dentists in the DHR.7 The diagnosis of RA was confirmed by the rheumatologist at the time of the recruitment into EIRA; blood samples were collected to determine ACPA/RF status.8 Detailed information on smoking status was collected by a self-administered questionnaire at the time of enrolment to EIRA.8 For the association between smoking status, seropositive/seronegative RA and periodontitis, we calculated OR with 95% CI adjusted for age, gender, education and residential area.
In ACPA-positive RA, smoking was associated with a significantly (p<0.05) higher prevalence of periodontitis, mainly in current smokers (OR=1.9, 95% CI 1.5 to 2.5) (table 1). The highest prevalence of periodontitis, with almost a threefold increased risk, was observed among current smoking ACPA-positive men (OR=2.9, 95% CI 1.6 to 5.3). For ACPA-negative RA, no convincing association between smoking and periodontitis was observed (table 1). Similar associations (p<0.05) were observed in analysis based on RF status (RF-positive current smokers; OR=1.9, 95% CI 1.5 to 2.5) with the highest OR observed in RF-positive current smoking men (OR=2.9, 95% CI 1.6 to 5.2) (table not shown).
Interestingly, the OR for periodontitis increased even further among patients double positive for ACPA and RF antibodies, with OR of 3.3 (95% CI 1.8 to 6.2) observed in current smoking men compared with never smokers (table 2).
We herein demonstrate that the previously observed association between smoking and periodontitis in RA7 is confined to patients with seropositive RA, especially those with both ACPA and RF antibodies. One reason for the increased risk of periodontitis in seropositive RA may be due to enhanced ACPA and/or RF titres in smokers since smoking is reported to be associated with increased risk for seropositive RA and higher titres of ACPA/RF in RA, and furthermore, periodontitis has been associated with increased levels of ACPA/RF in patients with RA.1 4 5 9 10 Smoking did not, however, significantly increase the prevalence of periodontitis in ACPA-negative/RF-negative RA, suggesting different pathophysiological mechanisms depending on autoantibody status in patients with RA. Our results are in line with previous findings that seropositive and seronegative RA represent distinct disease subsets differing in several aspects, including the association between seropositive RA with specific genetic and environmental risk factors such as human leukocyte antigen (HLA)-shared epitope and smoking.4 5 In summary, the highest risk of periodontitis in patients with established RA was observed among seropositive current smokers, especially those double positive for ACPA and RF antibodies, a finding that warrants awareness by clinicians and their patients as well as further investigations on the mechanisms behind this association.
The authors thank all the EIRA participants, clinicians and research nurses and the investigators and founders of the EIRA study. We also thank Lena Israelsson and Hiba Mahdi for analysing the presence of anti-CCP2 antibodies in EIRA.
Contributors TY-L, LK, LA, KL, JA and AIC conceived and designed the study. TY-L, LN and KE acquired and analysed the data. The statistical analysis was conducted by LN. Interpretation of data was made by TY-L, KE, LA, LK, KL, JA and AIC. KE and TY-L drafted the manuscript. All authors revised the article for important intellectual content and approved the final version for publication.
Funding This work was supported by the collaborative European Union’s FP7 Research Projects—Gums & Joints (grant agreement no FP7-HEALTH-2010-261460) and TRIGGER (grant agreement no FP7-HEALTH-2013-306029), the Stockholm County Council (SOF and ALF), the Swedish Research Council, the Swedish Dental Society, the Swedish Rheumatic Foundation and Karolinska Institutet.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Regional Ethics Board in Stockholm approved the study design and written consent was obtained from all subjects.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.